This message contains images. If you don't see images, click here to view.
Click here to advertise in this news brief.




Text Version  RSS  Subscribe  Unsubscribe  Archive  Media Kit

Home   About AST   Education   Meetings & Events   Public Policy   Contact Us  

 




SOCIETY NEWS


Live webinars next week — free to AST members
AST
Register now for these upcoming webinars:
Feb. 18 at 2 p.m. EST: Complying with New UNOS Living Donor Care Policies (free to AST members, $25 for non-members)
Feb. 21 at 4 p.m. EST: Pathology Webinar for Fellows (free to everyone)

Check out www.myAST.org/education for all upcoming and on demand webinars!

Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article


PRODUCT SHOWCASE
  UCLA Immunogenetics Center

The UCLA Immunogenetics Center (UIC) provides comprehensive testing for organ and tissue transplantation. Transplant testing has a long history at UCLA. HLA typing was pioneered here in the 1960's. The development of the microcytoxicity test in 1964 marked the beginning of international testing and standardization of HLA typing. The UCLA Immunogenetics Center has retained its leadership position in HLA research, and in the development of accompanying diagnostic testing. MORE
 


Participate in the AST Institutional Support Program
AST
The AST offers numerous programs for transplant professionals and the support of the community is critically important to the success of the society's programs. By participating in the Institutional Support Program, your center's tax-deductible contribution of $3,000 will increase exposure for your center through electronic marketing, literature, and signage displays, as well as these other valuable benefits. In addition, your institution will be seen throughout the transplant community as having a vested interest in advancing the field of transplantation and improving patient care. Click here to participate in AST's Institutional Support Program, or contact Liz Piegzik, AST Associate Meeting Manager at lpiegzik@myAST.org.

AST thanks the following organizations for their participation in the 2014 Institutional Support Program:
    University of Michigan Transplant Center
    Children's Hospital of Pittsburgh of UPMC

Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE




Become an AST Corporate Affiliate
AST
The AST Corporate Affiliates Program provides an exciting opportunity for companies to support the work of the AST and receive tangible benefits throughout the year.

Benefits of participation include increased visibility, enhanced engagement opportunities, access to new marketing tools, and up-to-date communication about the latest research and advocacy efforts in the field of transplantation. In addition to these benefits, companies participating in this program are invited to meet annually with senior AST leadership to engage in strategic discussions about key issues impacting the field of transplantation.

Click here for additional information, or contact Liz Piegzik, Associate Meeting Manager, at lpiegzik@myAST.org.

AST thanks the following companies for their participation in the 2014 Corporate Affiliates Program:
    Genentech, A Member of the Roche Group
    Novartis Pharmaceuticals
    Roche Diagnostics Corporation
    Veloxis Pharmaceuticals

Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


TRANSPLANT NEWS


High CTLA-4 expression on Th17 cells results in increased sensitivity to CTLA-4 Coinhibition and resistance to belatacept
American Journal of Transplantation (login required)
The CD28/cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocker belatacept selectively inhibits alloreactive T cell responses but is associated with a high incidence of acute rejection following renal transplantation, which led us to investigate the etiology of belatacept–resistant graft rejection. T cells can differentiate into functionally distinct subsets of memory T cells that collectively enable protection against diverse classes of pathogens and can cross-react with allogeneic antigen and mediate graft rejection.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Intestinal transplantation in children with multiple intestinal atresias and immunodeficiency
Pediatric Transplantation (login required)
GVHD has been reported in 8–10% of children after small bowel transplant (SBTx). Immunodeficient children may be predisposed to aggressive, steroid-resistant GVHD. There exists a unique association of immunodeficiency in children with MIA (MIAI). in this study, authors report on their SBTx experience in patients with the diagnosis of MIAI, high incidence of GVHD, and the possible role of stem cell transplantation in these patients.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Featured Advertisers




Astellas is entering its 20th year focusing on transplant immunology. Today we remain steadfast in our commitment to advancing the field. Tomorrow we will seek new possibilities to help improve the transplant experience. Together. Please visit astellas.us
University of Utah - Multi-Organ Transplant Surgeon

The University Of Utah Department Of Surgery is seeking applications for a faculty member to join the multi-organ transplant team at the assistant professor level. This is an opportunity to join an expanding program and a cohesive group of transplant surgeons focused on excellence. The candidate should be board certified in general surgery and have completed an ASTS approved transplantation surgery fellowship. Apply here


Designs for Vision

The purpose of Surgical Telescopes is to enhance or magnify an image to insure the highest quality results in surgical procedures. We take our responsibility to surgeons and their patients seriously so all of our Surgical Telescopes provide the TRUE magnification that is expected. More info


Study: Impact of the hepatopulmonary syndrome MELD exception policy on outcomes of patients after liver transplantation
NCBI
Patients with hepatopulmonary syndrome (HPS) are prioritized for liver transplantation (given exception points) due to their high pre- and post-transplantation mortality. However, few studies have evaluated the outcomes of these patients.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


CUSUM: New quality monitoring tools provided by the Scientific Registry of Transplant Recipients
American Journal of Transplantation (login required)
The Scientific Registry of Transplant Recipients (SRTR) has been providing data on transplant program performance through semi-annual release of program-specific reports (PSRs). A consensus conference held in February 2012 recommended that SRTR also supply transplant programs with tools such as the cumulative sum (CUSUM) technique to facilitate quality assessment and performance improvement. SRTR developed the process, methodologies, programming code and web capabilities necessary to bring the CUSUM charts to the community, and began releasing them to all liver, kidney, heart and lung programs in July 2013.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


FRAX predicts fracture risk in kidney transplant recipients
Transplantation (login required)
More than 30 percent of potential kidney transplant recipients have pre-existing anti-human leukocyte antigen antibodies. This subgroup has significantly lower transplant rates and increased mortality. Desensitization has become an important tool to overcome this immunological barrier. However, limited data is available regarding long-term outcomes, in particular for the highest risk group with a positive complement-dependent cytotoxicity crossmatch (CDC XM) before desensitization.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE




Impact of congenital heart disease on outcomes of pediatric heart-lung transplantation
Pediatric Transplantation (login required)
HLT is reserved for children with cardiopulmonary disease not amendable to alternative therapies. Children with CHD with or without ES may be considered for HLT. Outcomes of HLT in this population are not well described. To test the hypothesis that CHD without ES is associated with worse graft survival and identify factors associated with poor outcome, a retrospective analysis of the UNOS database was performed.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Sterile leukocyturia is associated with interstitial fibrosis and tubular atrophy in kidney allograft protocol biopsies
American Journal of Transplantation (login required)
Kidney allograft interstitial fibrosis and tubular atrophy is associated with a poorer renal function and outcome. In the current clinical practice, an early diagnosis can only be provided by invasive tests. In this study, authors aimed to investigate the association of sterile leukocyturia with Banff criteria histological findings in kidney allograft protocol biopsies.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Histologic phenotype on 1-year poosttransplantation biopsy and allograft Survival in HLA-incompatible kidney transplants
Transplantation (login required)
The correlation between histopathologic phenotypes and allograft outcomes among patients desensitized for donor-specific antibody (HLA-incompatible) is unknown. In this study, authors analyzed one-year biopsies from desensitized recipients transplanted between 1999 and 2010 and estimated graft survival for each histologic phenotype identified. Median time posttransplant for the one-year biopsy was 367 days (interquartile range 357-388 days) and median follow-up of all patients post-1-year biopsy was 42 months (interquartile range 19.5-65 months).
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


TRENDING ARTICLES
Missed last week's issue? See which articles your colleagues read most.

    Utility of gene expression profiling score variability to predict clinical events in heart transplant recipients (Transplantation)
Impact of IgM and IgG3 Anti-HLA alloantibodies in primary renal allograft recipients (Transplantation)
Usefulness of pulmonary capillary wedge pressure as a correlate of left ventricular filling pressures in pulmonary arterial hypertension (The Journal of Heart and Lung Transplantation)
AST Cutting Edge of Transplantation happening next week (AST)
Myocardial regeneration of the failing heart (Heart Failure Reviews)

Don't be left behind. Click here to see what else you missed.


Long-term outcomes of kidney transplantation across a positive complement-dependent cytotoxicity crossmatch
Transplantation (login required)
More than 30 percent of potential kidney transplant recipients have pre-existing anti-human leukocyte antigen antibodies. This subgroup has significantly lower transplant rates and increased mortality. Desensitization has become an important tool to overcome this immunological barrier. However, limited data is available regarding long-term outcomes, in particular for the highest risk group with a positive complement-dependent cytotoxicity crossmatch (CDC XM) before desensitization.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


The discard of deceased donor kidneys in the UK
Clinical Transplantation (login required)
It is essential to minimize the unnecessary discard of procured deceased donor kidneys, but information on discard rates and the extent to which discard can be avoided are limited. Analysis of the UK Transplant Registry revealed that the discard rate of procured deceased donor kidneys has increased from 5 percent in 2002-3 to 12 percent in 2011-12. A national offering system for hard-to-place kidneys was introduced in the UK in 2006 (the Declined Kidney Scheme), but just 13 percent of kidneys that were subsequently discarded until 2012 were offered through the scheme. In order to examine the appropriateness of discard, 20 consecutive discarded kidneys from 13 deceased donors were assessed to determine if surgeons agreed with the decision that they were not implantable.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Study: Multimodality therapy and liver transplantation for hepatocellular carcinoma
Transplantation (login required)
Hepatocellular carcinoma is a major cause of death among patients with cirrhosis. A standardized approach of multimodality therapy with intent-to-treat by transplantation for all patients with hepatocellular carcinoma was instituted at our transplant center in 1997. Data were prospectively collected to evaluate the impact of multimodality therapy on posttransplant patient survival, tumor recurrence and patient survival without transplantation.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Cerebral oedema is rare in acute-on-chronic liver failure patients presenting with high-grade hepatic encephalopathy
Liver International (login required)
Acute-on-chronic liver failure has a rapidly progressive disease course associated with significant mortality. The prevalence of clinically significant cerebral oedema in ACLF is unknown. We aimed to describe the prevalence of cerebral oedema in a cohort of ACLF adult (>18 years). Authors identified patients admitted to a single, specialist intensive care unit between January 2005 and January 2011 with high-grade hepatic encephalopathy (≥3) and a clinical picture of either ACLF or chronic liver disease (CLD). Patients who had undergone cranial CT imaging were identified and their imaging reviewed. The ACLF and CLD groups were compared.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE
 



AST eNews

Colby Horton, Vice President of Publishing, 469.420.2601
Download media kit

Courtney Hodges, Content Editor, 972.402.2604   
Contribute news


This edition of the AST eNews was sent to ##Email##. To unsubscribe, click here.

Recent issues
Feb. 7, 2014
Jan. 31, 2014
Jan. 24, 2014
Jan. 17, 2014






7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063